EYEGENE Inc.

전체메뉴열기
레나임 테라퓨틱스 EG-COVID VITAL DB BIOVIA
전체메뉴닫기

R & D

Myocardial Ischemia / Reperfusion Injury

Myocardial Ischemia/ Reperfusion Injury Overview

  • Myocardial Ischemia angina pectoris, myocardial infarction occurs when blood flow decreases or stops to a part of the heart, causing damage to the heart muscle. In acute myocardial infarction and treatment, multiple damage to microvasculature occurs around the cardiovascular network.
  • Death due to myocardial reperfusion injury after reperfusion.

Mechanism of Action

In-vivo Proof-of-Concept

Confirming microvascular normalization efficacy

Clinical Trial Status

  • Preclinical
    pharmacology
    test complete

    2011

  • Preclinical
    toxicology tests
    complete

    2012

  • Preclinical
    efficacy
    test complete

    2015

  • MFDS Phase1
    approval(KR)

    2017

  • MFDS Phase1
    Complete(KR)

    2018

  • MFDS Phase2
    Approval (KR)

    2019

  • T. +82-2-322-1687
  • F. +82-2-302-4359 / +82-2-324-8059
  • 본사 : [07528] 서울특별시 강서구 양천로 401 강서한강자이타워 B동 1211호
  • 연구소 : [10551] 경기도 고양시 덕양구 의장로 122-1 2층

COPYRIGHTⓒ 2019 EYEGENE lnc. LTD. All RIGHTS RESERVED.